This is a clean Phase 1a safety readout with encouraging efficacy signals (64% stable disease rate in heavily pre-treated metastatic patients). The stock is a micro-cap ($5M market cap) with limited float, so any positive catalyst can produce outsized moves. Watch for Phase 2a enrollment updates and presentation of full data at future scientific congresses. The company's going concern risk remains a key overhang — monitor for financing needs.
Price Chart
Executive Summary
TransCode Therapeutics announced successful completion of its Phase 1a dose escalation trial for TTX-MC138 in metastatic cancer. The trial met its primary safety endpoint with no dose-limiting toxicities, and 64% of evaluable patients achieved stable disease for six months. The company is advancing to Phase 2a development in ctDNA-positive colorectal cancer.
Key Facts
- Phase 1a trial met primary safety endpoint with no dose-limiting toxicities across all 4 cohorts (0.8-4.8 mg/kg)
- 16 patients received 86 doses; median treatment duration 11.3 weeks (range 4-52.4 weeks)
- 9 of 14 evaluable patients (64%) achieved stable disease lasting six months per RECIST criteria
- Three patients remain on study at 21, 16, and 14 cycles of treatment
- One metastatic thyroid cancer patient had a dramatic decrease in thyroglobulin levels with stable disease for 12 months
- Recommended Phase 2a dose (RP2D) selected at 4.8 mg/kg
- Phase 2a trial in ctDNA-positive colorectal cancer has been initiated
Financial Impact
No financial figures provided; pre-revenue clinical-stage company with $5M market cap
Risk Factors
- Company has going concern risk and needs additional funding to continue operations
- Phase 1a was open-label, single-arm with small sample size (16 patients) — efficacy signals are preliminary
- Phase 2a in ctDNA-positive colorectal cancer is a different indication and may not replicate these results
- Micro-cap stock with $5M market cap is highly volatile and illiquid
- No revenue or near-term approval path; binary catalyst risk on every data readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-069810 |
| Document: tm2616719d1_ex99-1.htm | 0001104659-26-069810 |
| Document: 0001104659-26-069810-index-headers.html | 0001104659-26-069810 |
| Document: 0001104659-26-069810-index.html | 0001104659-26-069810 |
| Document: 0001104659-26-069810.txt | 0001104659-26-069810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.71 (−0.23%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.71 (−3.62%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.71 (−3.39%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.71 (−80.19%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.71 (−63.70%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.71 (−66.15%) |
May 26, 2026 21w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.71 (+68.35%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.71 (+78.21%) |
Apr 7, 2026 28w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.71 (+80.39%) |
Mar 3, 2026 33w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.71 (−82.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers